What is Empatica?
Empatica operates at the critical intersection of artificial intelligence, medical device engineering, and digital health. The company specializes in the development of sophisticated wearable devices that capture high-fidelity physiological signals, including electrodermal activity, heart rate variability, and skin temperature. These data points are processed through advanced machine learning models to provide actionable, clinically meaningful insights for researchers, pharmaceutical companies, and healthcare providers.
By enabling continuous monitoring outside of traditional clinical environments, Empatica addresses a significant void in neurological care and chronic disease management. Its platform serves as a vital tool for digital biomarker discovery, allowing for the objective measurement of patient health in real-world settings. This capability is increasingly sought after by clinical researchers who require precise, longitudinal data to evaluate treatment efficacy and patient outcomes.
How much funding has Empatica raised?
Empatica has raised a total of $7.8M across 3 funding rounds:
Angel/Seed
$2M
Angel/Seed
$782K
Series A
$5M
Angel/Seed (2014): $2M, investors not publicly disclosed
Angel/Seed (2015): $782K, investors not publicly disclosed
Series A (2017): $5M, investors not publicly disclosed
Key Investors in Empatica
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Empatica?
With the recent influx of capital, Empatica is well-positioned to accelerate its enterprise-level growth strategy. The focus will likely shift toward expanding the clinical utility of its digital biomarkers and deepening its integration within pharmaceutical research pipelines. As the demand for remote patient monitoring continues to rise, the company is expected to scale its infrastructure to support larger, multi-site clinical trials and potentially explore new therapeutic areas beyond its current neurological focus.
Strategic priorities will likely include the refinement of its proprietary sensor fusion technology and the expansion of its data analytics capabilities. By maintaining its commitment to medical-grade accuracy, Empatica is poised to remain a cornerstone of the digital health revolution, providing the necessary data architecture to support the future of decentralized clinical trials and personalized medicine.
